SUMMARY. Numerous current investigations in the field of experimental oncology have demonstrated that the results of fundamental studies, conducted on current methodological level, may serve as a considerable foundation for their application in the clinical practice. To determine the inhibiting effect of exogenous lactoferrin (LF) in the doses of 1 and 10 mg/kg of the bodyweight of animals in the system in vivo, using Walker-256 carcinosarcoma, the safety of its application, the specificities of changes in cytoarchitectonics of the tumour tissue, the disturbance in the indices of energy exchange and essential homeostasis on the level of the tumour and organism, as well as associative connections and mechanisms, conditioning the abovementioned transformations. Outbred rats with grafted Walker-256 carcinosarcoma, which were abdominally administered exogenous LF nine times in the doses of 1 and 10 mg/kg of the bodyweight of animals, and the animals, which served as a control, were used. The morphological method of estimating the changes in cytoarchitectonics of tumours under the impact of LF was applied. The safety of applying exogenous LF was determined using the cytogenetic method of Hayashi. The content of essential elements was determined using the method of atomic-emission spectroscopy, the content of energy exchange indices was defined using the atomic biochemistry and immunoenzymatic analyzer. It was determined that exogenous LF in the investigated doses leads to inhibiting the growth of Walker-256 carcinosarcoma, which is manifested in unidirectional changes in its architectonics: the segregation of tumour cells, pycnosis, hyperchromatosis of nuclei, necrobiosis phenomena, necrosis and, as a result of the decrease in the total number of tumour cells, – dilatation of vessels, thinning of walls, hemorrhages. There are changes in the bioenergetic phenotype of tumour cells: the decrease in the content of glucose and lactate. The impact of LF leads to the impairment of the homeostasis of essential elements, including calcium, iron, zinc in the tumour tissue and blood plasma. The mechanisms, which may condition the abovementioned effect of LF, were determined based on the conducted studies of impairments in tumour cytoarchitectonics, including the vessels, under the effect of exogenous LF.
Keywords: Walker-256 carcinosarcoma, exogenous lactoferrin, tumour cytoarchitectonics, energy exchange, glucose, lactate, essential elements
Full text and supplemented materials
References
1. Chamaraux-Tran, T.N., Mathelin, C., Aprahamian, M., Joshi, G.P., Tomasetto, C., Diemunsch, P., and Akladios, C, Antitumor effects of lidocaine on human breast Cancer cells: an in vitro and in vivo experimental trial, Anticancer Res., 2018, vol. 38, no. 1, pp. 95–105. https://doi.org/10.21873/anticanres.12196
2. Monti, D., Sotgia, F., Whitaker-Menezes, D., Tuluc, M., Birbe, R., Berger, A., Lazar, M., Cotzia, P., Draganova-Tacheva, R., Lin, Z., Domingo-Vidal, M., Newberg, A., Lisanti, M.P., and Martinez-Outschoorn, U., Pilot study demonstrating metabolic and anti-proliferative effects of in vivo anti-oxidant supplementation with N-acetylcysteine in breast cancer, Semin. Oncol., 2017, vol. 44, no. 3, pp. 226–232. https://doi.org/10.1053/j.seminoncol.2017.10.001
3. Recalcati, S., Minotti, G., and Cairo, G., Iron regulatory proteins: from molecular mechanisms to drug development, Antioxid. Redox Signal., 2010, vol. 13, no. 10, pp. 1593–1616. https://doi.org/10.1089/ars.2009.2983
4. Khoo, T.C., Tubbesing, K., Pham, C, Desta, H., Sharikova, A., Barroso, M., and Khmaladze, A., Raman hyperspectral imaging of transferrin-bound iron in cancer cells. In Label-Free Biomedical Imaging and Sensing (LBIS), Int. Soc. Opt. Photon., 2019, vol. 10890. https://doi.org/10.1117/12.2511397
5. Cutrin, J.C., Alberti, D., Bernacchioni, C, Ciambellotti, S., Turano, P., Luchinat, C, Crich, S.G., and Aime, S., Cancer cell death induced by ferritins and the peculiar role of their labile iron pool, Oncotarget, 2018, vol. 9, no. 46, p. 27974. https://doi.org/10.18632/oncotarget.25416
6. Fernández-Menéndez, S., Fernández-Sánchez, M.L., González-Iglesias, H., Fernández-Colomer, B., Lopez-Sastre, J., and Sanz-Medel, A., Iron bioavailability from supplemented formula milk: effect of lactoferrin addition, Eur. J. Nutr., 2017, vol. 56, no. 8, pp. 2611–2620. ISSN 0564-3783.https://doi.org/10.1007/s00394-016-1325-7
7. Orlandi, R., De Bortoli, M., Ciniselli, C.M., and Vaghi, E.D., Hepcidin and ferritin blood level as noninvasive tools for predicting breast cancer, Ann. Oncol., 2014, vol. 25, no. 2, pp. 352–357. https://doi.org/10.1093/annonc/mdt490
8. Legrand, D. and Maurier, J., A critical review of the roles of host lactofferin in immunity, Biometals, 2010, vol. 23, no. 3, pp. 365–376. https://doi.org/10.1007/s10534-010-9297-1
9. Kang, Nam Mi, Cho, Ssang-Goo, Dayem, Ahmed Abdal, Lee, Joohyun, Bae, Seong Phil, Hahn, Won-Ho, and Lee, Jeong-Sang, The effects of human milk proteins on the proliferation of normal, cancer and cancer stem like cells, Anal. Sci. Technol., 2018, vol. 31, no. 6, pp. 232–239. https://doi.org/10.5806/AST.2018.31.6.232
10. Chekhun, V.F., Zalutskii, I.V., Naleskina, L.A., Lukianova, N.Y., Yalovenko, T.M., Borikun, T.V., Sobchenko, S.O., Semak, I.V., and Lukashevich, V.S., Modifying effects of lactoferrin in vitro on molecular phenotype of human breast cancer cells with varying degrees of malignancy and sensitivity of cytostatics, Exp. Oncol., 2015, vol. 37, vol. 3, pp. 181–186. URI: http:// dspace.nbuv.gov.ua/handle/123456789/145485
11. Chekhun, V.F., Lukianova, N.Yu., Polishchuk, L.Z., Nalieskina, L.A., Zadvornyi, T.V., Storchai, D.M., Todor, I.N., Sobchenko, S.O., Demash, D.V., Yalovenko, T.M., Borikun, T.V., Lozovska, Yu.V., Vitruk, Yu.V., Chepurnatyi, M.V., Pikul, M.V., Stakhovsky, O.E., Voilenko, O.A., and Stakhovsky E.O., The role of lactoferrin expression in initiation and progression of most common hormone-dependent cancers, Horiz. Cancer Res., 2017, vol. 66, chapter 3, pp. 51–85. https://novapublishers.com/shop/horizons-in-cancer-research-volume-66/
12. Koblyakov, A.V., Antoshina, E.E., Gorkova, T.G., and Goldman, I.L., The inhibitory effect of human lactoferrin (neolactoferrin) on the growth of an inoculated tumor of the cervix of mice, Vopr. Onkol., 2012, vol. 58, no. 5, pp. 668–673. https://elibrary.ru/item.asp?id=17989425
13. Zhang, Y., Lima, C.F., and Rodrigues, L.R., In vitro evaluation of bovine lactoferrin potential as an anticancer agent, Int. Dairy J., 2015, vol. 40, no. 2015, pp. 6–15.https://doi.org/10.1016/j.idairyj.2014.08.016
14. Iglesias-Figueroa, B.F., Siqueiros-Cendyn T.S., Gutierrez D.A, Aguilera, R.J., Espinoza-Sánchez, E.A., Arévalo-Gallegos, S., Varela-Ramirez, A., and Rascyn-Cruz, Q. Recombinant human lactoferrin induces apoptosis, disruption of F-actin structure and cell cycle arrest with selective cytotoxicity on human triple negative breast cancer cells, Apoptosis, 2019, pp. 1–16. https://doi.org/10.1007/s10495-019-01539-7
15. Terpinskaya, T.I., Pavlovets, L.V., The effect of human lactoferrin obtained from the milk of transgenic goats on the growth of transplantable tumors in mice, Healthcare (Minsk, Belarus), 2013, vol. 2, pp. 33–37. http://elib.bsu.by/ itstream/123456789/17272/1/133.pdf
16. Zalutsky, I.V., Lukashevich, V.S., Lukyanova, N.Yu., Kondrashova, S.B., Rudnichenko, Yu.,A., Basalay, A.A., and Chekhun, V.F., Effect of exogenous lacto-ferrin on the development of an experimental model of breast carcinoma, Rep. Nat. Acad. Sci. Belarus, 2017, vol. 61, no. 5, pp. 103–108. https://doklady.belnauka.by/jour/ ar ticle/view/463? locale=ru_RU
17. Nicoletti, G., Migliorati, M., Pagliacci, C., Grignani, F., and Riccardi, C., A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry, J. Immunol. Methods, 1991, vol. 139, pp. 271–279. https://doi.org/10.1016/0022-1759(91)90198-o
18. Tinwell, H. and Ashby, J., Comparison of Acridine orange and Gimsa stains in several mouse bone marrow micronucleus assay—including a triple dose study, Mutagenesis, 1989, vol. 6, no. 3, pp. 476–481. https://doi.org/10.1093/mutage/4.6.476
19. Dias, V.M., Oliveria, R.M., and Machado-Santelli, G.M., Using fluorescence for improvement of the quantitative analysis of micronucleus in cell culture, Mutat. Res., 2005, vol. 565, pp. 173–179. https://doi.org/10.1016/j.mrgentox.2004.10.003
20. Andrusishina, I.M., Lampeka, O.G., and Golub, I.O., Estimation of the damage to the professional community in professional contingents for the additional method of atomic energy spectroscopy from inductively coupled plasma, UkrTsNMI and the PCR of the registry No. 72-K, Avitsen, 2014, p. 60.
21. Vorobyova, O.V., Novichkov, E.V., Quantitative morphometry of endometrial ovarian cancer at risk of metastasis, Med. News North. Cauc., 2015, vol. 10, no. 3, pp. 254–258. https://doi.org/10.14300/mnnc.2015.00059
22. Gibbons, J.A., Kanwar, J.R., and Kanwar, R.K., Iron-free and iron-saturated bovine lactoferrin inhibit survivin expression and differentially modulate apoptosis in breast cancer, BMC Cancer, 2015, vol. 15, no. 1, p. 425. https://doi.org/10.1186/s12885-015-1441-4
23. Blais, A., Fan, C., Voisin T., Aattouri, N., Dubarry, M., Blachier, F., and Tome, D., Effects of lactoferrin on intestinal epithelial cell growth and differentiation: an in vivo and in vitro study, Biometals, 2014, vol. 27, no. 5, pp. 857–874. https://doi.org/10.1007/s10534-014-9779-7
24. Sharma, R., Chakraborty, D., and Gupta, P., Bovine lactoferrin and its functions in animals—a review, Agric. Rev., 2015, vol. 36, no. 4, pp. 321–326. doi 10.18805/ag.v36i4.6669. ISSN 0564–3783.
25. Tammam, S.N., Azzazy, H.M., and Lamprecht, A., Nuclear and cytoplasmic delivery of lactoferrin in glioma using chitosan nanoparticles: cellular location dependent-action of lactoferrin, Eur. J. Pharm. Biopharm., 2018, vol. 129, pp. 74–79.https://doi.org/10.1016/j.ejpb.2018.05.027
26. Sokolov, A.V., Zakahrova, E.T., Kostevich, V.A., Samygina, V.R., and Vasilyev, V.B., Lactoferrin, myeloperoxidase, and ceruloplasmin: complementary gearwheels cranking physiological and pathological processes, BioMetals, 2014, vol. 27, no. 5, pp. 815–828. https://doi.org/10.1007/s10534-014-9755-2
27. Lozovska, Y.V., Andrusishina, I.M., Lukianova, N.Y., Burlaka, A.P., Naleskina, L.A., Todor, I.N., and Chekhun, V.F., The influence of lactoferrin on elemental homeostasis and activity of metal-containing enzymes in rats with Walker-256 carcinosarcoma, Exp. Oncol., 2019, vol. 41, no 1, pp. 20–25. https://doi.org/10.32471/exp-oncology.2312-8852.vol-41-no-1.12471
28. Ambrosone, C.B., Barlow, W.E., and Reynolds, W., Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-889, J. Clin. Oncol., 2009, vol. 27, no. 4973–4979. https://doi.org/10.1200/JCO.2009.21.8669
29. Rymaszewski, A.L., Tate, E., and Yimbesalu, J.P., The role of neutrophil myeloperoxidase in models of lung tumor development, Cancers (Basel), 2014, vol. 6, no. 2, pp. 1111–1127. https://doi.org/10.3390/cancers6021111
30. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation, Cell, 2011, vol. 144, no. 5, pp. 646–674. https://doi.org/10.1016/j.cell.2011.02.013
31. Smolková, K., Plecitá-Hlavatá, L., Bellance, N., Benard, G., Rossignol, R., and Ježek, P., Waves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells, Int. J. Biochem. Cell Biol., 2011, vol. 43, no. 7 pp. 950–968.https://doi.org/10.1016/j.biocel.2010.05.003
32. Nguyen, D.N., Jiang, P., Stensballe, A., Bendixen, E., Sangild, P.T., and Chatterton, D.E., Bovine lactoferrin regulates cell survival, apoptosis and inflammation in intestinal epithelial cells and preterm pig intestine, Proteomics, 2016, vol. 139, pp. 95–102. https://doi.org/10.1016/j.jprot.2016.03.020
33. Weijer, R., Broekgaarden, M., Krekorian, M., Alles, L.K., van Wijk, A.C., Mackaaij, C., Verheij, J., van der Wal, A.C., van Gulik, T.M., Storm, G., and Heger, M., Inhibition of hypoxia inducible factor 1 and topoisomerase with acriflavine sensitizes perihilar cholangiocarcinomas to photodynamic therapy, Oncotarget, 2016, vol. 7, no. 3, pp. 3341–3356. https://doi.org/10.18632/oncotarget.6490
34. Singh, M., Kumar, D., Singh, G., and Deepak, S., Natural minerals and cancer, J. Appl. Pharm. Sci., 2012, vol. 4, pp. 158–165. https://doi.org/10.7324/JAPS.2012.2513
35. Frederickson, C.J., Koh, J-Y., and Bush, A.I., The neurobiology of zinc in health and disease, Nat. Rev. Neurosci., 2005, vol. 6, 449–462. https://doi.org/10.1038/nrn1671
36. Andreini, C. and Bertini, I., A bioinformatics view of zinc enzymes, J. Inorg. Biochem., 2012, vol. 111, pp. 150–156. https://doi.org/10.1016/j.jinorgbio.2011.11.020
37. MacDonald, R.S., The role of zinc in growth and cell proliferation, J. Nutr., 2000, vol. 130, suppl, pp. 1500S–1508S. https://doi.org/10.1093/jn/130.5.1500S
38. Bellomo, E., Massarotti, A., Hogstrand, C., and Maret, W., Zinc ions modulate protein tyrosine phosphatase 1B activity, Metallomics, 2014, vol. 6, pp. 1229–1239. https://doi.org/10.1039/c4mt00086b
39. Zhu, D., Su, Y., Zheng, Y., Fu, B., Tang, L., and Qin, Y.X., Zinc regulates vascular endothelial cell activity through zinc-sensing receptor ZnR/GPR39, Am. J. Physiol. Cell Physiol., 2018, vol. 314, pp. C404–C414. https://doi.org/10.1152/ajpcell.00279.2017
40. Ma, J., Zhao, N., and Zhu, D., Endothelial cellular responses to biodegradable metal zinc. ACS, Biomater. Sci. Eng., 2015, vol. 1, no. 11, pp. 1174–1182. https://doi.org/10.1021/acsbiomaterials.5b00319
41. Munaron, L and Pla, A.F., Endothelial calcium machinery and angiogenesis: understanding physiology to interfere with pathology, Curr. Med. Chem., 2009, vol. 16, no. 35, pp. 4691–4703. https://doi. rg/10.2174/092986709789878210
42. Wu, L, Du, Y., Lok, J., Lo, E.H., and Xing, C., Lipocalin-2 enhances angiogenesis in rat brain endothelial cells via reactive oxygen species and iron-dependent mechanisms, J. Neurochem., 2015, vol. 132, no. 6, pp. 622–628. https://doi.org/10.1111/jnc.13023
43. Yang, J., McNeish, B., Butterfield, C., and Moses, M.A., Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer, FASEB J., 2013, vol. 27, pp. 45–50. https://doi.org/10.1096/fj.12-211730
44. Suzuki, H., Ikeda, N., Kobayashi, K., Terashima, Y., Shimada, Y., Suzuki, T., Hagiwara, T., Hatakeyama, S., Nagaoka, K., Yoshida, J., Saito, Y., Tanaka, J., and Hayashi, M., Evaluation of liver and peripheral blood micronucleus assay with 9 chemicals using young rats a study by the Collaborative Study Group for the Micronucleus Test(CSGMT). Japanese Environmental Mutagen Society (JEMS)—Mammalian Mutagenicity Study Group (MMS), Mutat. Res., 2005, vol. 583, pp. 133–145. https://doi.org/10.1016/j.mrgentox.2005.03.012
45. Celik, A., Ogenler, O., and Comelekoglu, U., The evaluation of micronucleus freguenc by acridine orange fluorescent staining in peripheral blood of rats treated with lead acetate, Mutagenesis, 2005, vol. 20, no. 6, pp. 411–415. https://doi.org/10.1093/mutage/gel027